Abstract

BackgroundPaclitaxel is a widely prescribed chemotherapy drug for treating solid tumors. However, paclitaxel-induced peripheral neuropathy (PIPN) is a common adverse effect during paclitaxel treatment, which results in sensory abnormalities and neuropathic pain among patients. Unfortunately, the mechanisms underlying PIPN still remain poorly understood. Long noncoding RNAs (lncRNAs) are novel and promising targets for chronic pain treatment, but their involvement in PIPN still remains unexplored.MethodsWe established a rat PIPN model by repetitive paclitaxel application. Immunostaining, RNA sequencing (RNA-Seq) and bioinformatics analysis were performed to study glia cell activation and explore lncRNA/mRNA expression profiles in spinal cord dorsal horn (SCDH) of PIPN model rats. qPCR and protein assay were used for further validation.ResultsPIPN model rats developed long-lasting mechanical and thermal pain hypersensitivities in hind paws, accompanied with astrocyte and microglia activation in SCDH. RNA-Seq identified a total of 814 differentially expressed mRNAs (DEmRNA) (including 467 upregulated and 347 downregulated) and 412 DElncRNAs (including 145 upregulated and 267 downregulated) in SCDH of PIPN model rats vs. control rats. Functional analysis of DEmRNAs and DElncRNAs identified that the most significantly enriched pathways include immune/inflammatory responses and neurotrophin signaling pathways, which are all important mechanisms mediating neuroinflammation, central sensitization, and chronic pain. We further compared our dataset with other published datasets of neuropathic pain and identified a core set of immune response-related genes extensively involved in PIPN and other neuropathic pain conditions. Lastly, a competing RNA network analysis of DElncRNAs and DEmRNAs was performed to identify potential regulatory networks of lncRNAs on mRNA through miRNA sponging.ConclusionsOur study provided the transcriptome profiling of DElncRNAs and DEmRNAs and uncovered immune and inflammatory responses were predominant biological events in SCDH of the rat PIPN model. Thus, our study may help to identify promising genes or signaling pathways for PIPN therapeutics.

Highlights

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting neurotoxic adverse effect of many chemotherapeutic agents [1]

  • We found that the protein expression of CCL3 is significantly increased in spinal cord tissue from paclitaxeltreated rats compared with control rats (Fig. 5f)

  • We found a number of differentially expressed mRNAs and Long noncoding RNA (lncRNA)

Read more

Summary

Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting neurotoxic adverse effect of many chemotherapeutic agents [1]. Paclitaxel-induced peripheral neuropathy (PIPN) is a common and serious side effect accompanying paclitaxel treatment [1]. Conventional treatments for paclitaxel-induced peripheral neuropathic pain include nonsteroidal anti-inflammatory drugs, opioids, corticosteroids, and antidepressants [10]. These medical treatments are usually insufficient for paclitaxel-induced peripheral neuropathic pain management and oftentimes resulted in a number of severe side effects [10]. Paclitaxel-induced peripheral neuropathic pain still remains a challenging clinical problem for patients receiving chemotherapy. Paclitaxelinduced peripheral neuropathy (PIPN) is a common adverse effect during paclitaxel treatment, which results in sensory abnormalities and neuropathic pain among patients. Long noncoding RNAs (lncRNAs) are novel and promising targets for chronic pain treatment, but their involvement in PIPN still remains unexplored

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call